




RealRate

PHARMACEUTICAL 2021

Alaunos Therapeutics Inc
Rank 134 of 394

ALAUNOS[™]
THERAPEUTICS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Alaunos Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alaunos Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Alaunos Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 319%, being 63% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	130,589
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,368
Liabilities, Non-Current	0
Other Assets	5,525
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3,995
Other Net Income	385
Other Revenues	0
Property and Equipment	10,231
Research and Development	52,696
Selling, General and Administrative Expense	27,665

Output Variable	Value in 1000 USD
Assets	146,345
Liabilities	22,363
Expenses	80,361
Revenues	0
Stockholders Equity	123,982
Net Income	-79,976
Comprehensive Net Income	-79,976
BaseVar	124,727
ECR before LimitedLiability	226%
Economic Capital Ratio	319%